ncRNA basic information
ncRNA ID:
MIMAT0002881
ncRNA Database:
miRBase
ncRNA Name:
miR-509-3p
ncRNA Type:
miRNA
ncRNA Expression:
down-regulated
ncRNA Method:
RT-qPCR
ncRNA Target Gene:
GOLPH3 and WLS
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
Our study aims on identifying role of miRNAs in drug-resistance of platinum in ovarian cancer. In present study, we compared the expression profiles of miRNAs between three pairs of platinum-resistant and platinum-sensitive ovarian tissues and found that miR-509-3p was significantly down-regulated in cisplatin-resistant ovarian cancer tissues. The different expression of miR-509-3p was further determined by RT-qPCR analyses of tissue samples from groups of 20 patients with cisplatin-sensitive ovarian cancer and 7 patients with cisplatin-resistant ovarian cancer. Functional studies demonstrated that miR-509-3p inhibitor decreased cell response to cisplatin (CDDP) and promoted cell survival in SKOV3 ovarian cancer cells. Furthermore, we found gene expression level of Golgi phosphoprotein-3 (GOLPH3) and wntless Wnt ligand secretion mediator (WLS) were regulated by miR-509-3p. The direct bindings of miR-509-3p to GOLPH3 and WLS genes were confirmed by dual-luciferase reporter assay. And the negative correlation between their expression levels in SKOV3 cells was further verified with RT-qPCR.
Drug Response:
resistant
Cancer basic information
Cancer:
ovarian cancer
Tissue/Cell:
cell line (HEK-293A,SKOV3)
Other information
Title:
miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Journal:
Gene
Published:
2019
PubMed ID:
30408550